Key Details
Annual ROE
79.05%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Mar 22, 2023Recent annual earnings:
Mar 22, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
12 Jan '23 Barclays
Equal-Weight10 Jan '23 Morgan Stanley
Equal-Weight08 Dec '22 Barclays
Overweight07 Dec '22 Barclays
Overweight29 Nov '22 Oppenheimer
Perform29 Nov '22 Morgan Stanley
Equal-Weight28 Oct '22 Goldman Sachs
Buy09 Sept '22 Morgan Stanley
Overweight22 Aug '22 Piper Sandler
Overweight09 Aug '22 Morgan Stanley
OverweightScreeners with CINC included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
CinCor Pharma doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of CinCor Pharma?
- What is the ticker symbol for CinCor Pharma?
- Does CinCor Pharma pay dividends?
- What sector is CinCor Pharma in?
- What industry is CinCor Pharma in?
- What country is CinCor Pharma based in?
- When did CinCor Pharma go public?
- Is CinCor Pharma in the S&P 500?
- Is CinCor Pharma in the NASDAQ 100?
- Is CinCor Pharma in the Dow Jones?
- When was CinCor Pharma's last earnings report?
- When does CinCor Pharma report earnings?
- Should I buy CinCor Pharma stock now?
What is the primary business of CinCor Pharma?
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts. As of February 23, 2023, CinCor Pharma, Inc. operates as a subsidiary of AstraZeneca Finance and Holdings Inc..
What is the ticker symbol for CinCor Pharma?
The ticker symbol for CinCor Pharma is NASDAQ:CINC
Does CinCor Pharma pay dividends?
No, CinCor Pharma does not pay dividends
What sector is CinCor Pharma in?
CinCor Pharma is in the Healthcare sector
What industry is CinCor Pharma in?
CinCor Pharma is in the Biotechnology industry
What country is CinCor Pharma based in?
CinCor Pharma is headquartered in United States
When did CinCor Pharma go public?
CinCor Pharma's initial public offering (IPO) was on 07 January 2022
Is CinCor Pharma in the S&P 500?
No, CinCor Pharma is not included in the S&P 500 index
Is CinCor Pharma in the NASDAQ 100?
No, CinCor Pharma is not included in the NASDAQ 100 index
Is CinCor Pharma in the Dow Jones?
No, CinCor Pharma is not included in the Dow Jones index
When was CinCor Pharma's last earnings report?
CinCor Pharma's most recent earnings report was on 22 March 2023
When does CinCor Pharma report earnings?
The date for CinCor Pharma's next earnings report has not been announced yet
Should I buy CinCor Pharma stock now?
As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions